What the authors failed to realize is that many of the clinical trials were based on the guidelines for pharmaceutical drugs. Such trials have two main assumptions: (1) that the trial is the only source of the agent and (2) that there is a linear doseresponse relation. Neither assumption is satisfied for vitamin D trials. Heaney recently outlined the guidelines for trials of nutrients such as vitamin D.
T o the Editor:
The narrative review by Allan and colleagues concluded that while vitamin D supplementation provides some benefit in fracture prevention, it has not been demonstrated to prevent cancer, respiratory tract infections or rheumatoid arthritis. 1 What the authors failed to realize is that many of the clinical trials were based on the guidelines for pharmaceutical drugs. Such trials have two main assumptions: (1) that the trial is the only source of the agent and (2) that there is a linear doseresponse relation. Neither assumption is satisfied for vitamin D trials. Heaney recently outlined the guidelines for trials of nutrients such as vitamin D.
2 They include that the baseline 25-hydroxyvitamin D [25(OH)D] concentration should be measured, only those with low concentrations should be enrolled in the study, sufficient vitamin D should be given to raise concentrations to achieve significant reductions in the risk of health outcomes, and the achieved concentration should be measured. In addition, meta-analyses should only compare trials with similar conditions. A typical 25(OH)D concentration-health outcome relation is given for breast cancer in Figure 2 in a recent paper. 3 Risk decreases rapidly from 10 to 30 nmol/l, at a moderate rate from 30 to 60 nmol/l and slowly above 60 nmol/l. The percentile values of 25(OH)D concentrations for women aged over 50 years in the US for [2001] [2002] [2003] [2004] [2005] [2006] 4 can be used with the 25(OH)D-breast cancer incidence relation to estimate the reduction in breast cancer rates if all women achieved 100 nmol/ l, which could take about 4000 IU/day vitamin D 3 . The result is a 35 % reduction. This value compares well with the results from the Women's Health Initiative for those women not taking vitamin D or calcium prior to enrollment: taking 1500 mg/day calcium plus 400 IU/day vitamin D 3 by them significantly decreased the risk of total, breast and invasive breast cancers by 14-20 %. 5 Regarding respiratory tract infection clinical trials (Belief 3 in Ref. 1) , it is noted that in the trial from New Zealand finding no benefit for large-dose vitamin D 3 , the baseline 25(OH)D concentration was 72.5 nmol/l, which is in stark contrast to the trial from Mongolia finding significant benefits of 300 IU/day vitamin D 3 had a baseline concentration of 17.5 nmol/l.
Thus, more progress could be achieved in the near term if clinical trials were designed to evaluate 25(OH)D concentration-health outcome relations trying to determine whether giving vitamin D 3 supplements to the general public affects health outcomes.
